Cosette Pharmaceuticals, a Bridgewater, NJ-based specialty pharmaceutical company, acquired Intrarosa, a company focused on prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia, from Endoceutics, Inc., a subsidiary of Endorecherche, Inc.
The amount of the deal was not disclosed.
The acquisition accelerates Cosette’s women’s health portfolio with a differentiated, commercial stage, patent protected product. The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033 including 3 Orange Book listed patents.
Intrarosa specializes in prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia (a common symptom of vulvar and vaginal atrophy (VVA) due to menopause). Intrarosa® is currently available in almost all major markets, including the US, UK, EU, Canada, and Israel through local partners like Theramex, Tecnimede, Avia, Lupin (BSE: 500257), Dexcel, Labatec, Lacer, Lee’s Pharma, and Valenta; with Asian market launches in 2025.
Led by Apurva Saraf, President and CEO, Cosette Pharmaceuticals is a pharmaceutical company with capabilities in product development, manufacturing, and commercial operations that has a fast-growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and migraine indications. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. The company has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm.
FinSMEs
12/06/2023